ArticleACG case reports journal2026
Heterotopic Ossification in an Appendiceal Sessile Serrated Lesion With Synchronous Neuroendocrine Tumor.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Sessile serrated lesions of the appendix: a contemporary review of the literature.BMC gastroenterology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterotopic ossification (HO) in colorectal polyps is rare and scarcely reported in serrated lesions. We report an appendiceal sessile serrated lesion (SSL) with mature bone and a contiguous well-differentiated neuroendocrine tumor. A 64-year-old woman had a firm appendiceal-orifice polyp biopsied in 2012 showing calcification; SSL was identified in 2019. In 2024, an 8-mm lesion was removed en bloc by underwater cold snare; histology showed SSL with HO. Laparoscopic appendectomy confirmed residual SSL with HO and an adjacent 4.5-mm grade-1 neuroendocrine tumor (INSM1+, Ki-67 <3%) with negative margins. HO recognition should prompt en bloc excision and attentive pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.